WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement in support of the U.S. Senate’s approval of the Food and Drug Administration Safety and Innovation Act (FDASIA): “BIO commends the bipartisan Senate approval of FDASIA, which includes a reauthorization of the Prescription Drug User Fee Act (PDUFA).
